10 Stocks Racking Up Big Gains

6. ImmunityBio, Inc. (NASDAQ:IBRX)

ImmunityBio rallied for a second day on Friday, soaring 10.80 percent to end at $2.36 apiece, mimicking optimism of the broader market and loading positions ahead of expected updates from its participation in a global health conference next week.

According to ImmunityBio, Inc. (NASDAQ:IBRX), it would participate in the 37^th Piper Sandler Annual Healthcare Conference in New York from December 2 to 4.

Investors are expected to closely watch out for the company’s business updates and outlook related to its clinical pipelines.

Earlier this month, ImmunityBio, Inc. (NASDAQ:IBRX) narrowed its net loss attributable to shareholders by 21.6 percent to $67.25 million from $85.73 million in the same period last year, driven by increased product revenues and lower related-party interest expense.

Revenues soared by 425 percent to $32.06 million from $6.1 million year-on-year, thanks to strong sales from its non-muscle-invasive bladder cancer (NMIBC) treatment, Anktiva.